tbuckley/cabot-search huggingface dataset:
Differentiating asymptomatic monoclonal gammopathy (AMG including MGUS and AMM) from clinical multiple myeloma (CMM) by gene expression profiling of purified plasma cells (PC-GEP).
Authors: Rashid Khan, Christoph Johann Heuck, Adam Rosenthal, Madhav V. Dhodapkar, Scott E. Miller, Pingping Qu, Donald Joseph Johann, Frits Van Rhee, Yogesh Jethava, Maurizio Zangari, Shmuel Yaccoby, Phillip Farmer, Monica Grazziutti, Joshua Epstein, Antje Hoering, John Crowley, Bart Barlogie
Journal: Journal of Clinical Oncology (2014)

8604 Background: Previous research indicated that PC from AMG and CMM could not be distinguished at the GEP level. We reported that a GEP70 risk score could identify a subset of AMG patients at high risk for progression to CMM requiring therapy. We now re-address this issue in a larger population of patients (pts) in order to contribute to a better understanding of the genetics of this progression event from clinically benign to malignant disease. Methods: We identified baseline GEPs of 89 pts with AMG and 38 pts with MGUS in our observational study and compared them to 785 GEPs of previously untreated pts with MM who were enrolled in Total Therapy 2 and 3. GEPs were separated into training and test sets of 60 and 29 pts for AMM, 26 and 12 pts for MGUS and 524 and 261 pts for CMM respectively. We performed t-tests to identify differentially expressed probesets between AMM and CMM, MGUS and CMM and AMM and MGUS. Results adjusted for multiple testing and probesets were ranked by q-value for each comparison. Results: In the comparison between AMM and CMM we identified 74 probesets significantly differentially expressed with a q-value <1 X 10-6. Using a class predictor approach the log2 transformed expression values for each gene were summed. An optimal cutpoint was identified in the training set and validated in the test set, performance was satisfactory with a sensitivity of 79.3%, a specificity of 92.0% and a positive predictive (PPV) value of 90.7%. AMM samples classified as CMM had a significantly shorter time to progression to CMM than those classified as AMM. Conversely pts with CMM who were classified as AMM had a better PFS and OS than those classified as CMM. 206 genes were differentially expressed between MGUS and CMM and a predictive model based on these genes showed a sensitivity of 83%, specificity of 92.3% and PPV of 91.9%. 11 probesets were common between the AMM/CMM and MGUS CMM gene lists. Conclusions: Gene expression profiling can readily differentiate between MGUS or AMM and CMM. More importantly pts with AMM who have a CMM-like GEP signature have a significantly shorter time to progression to CMM while AMM-like signature in CMM predicts better outcome.
The prognostic value of body mass index in Hodgkin lymphoma and diffuse non-Hodgkin lymphoma.
Authors: Mehmet Turgut, Engin Kelkitli, Memis Hilmi Atay, Fatih Mehmet Cilingir, Bahiddin Yilmaz
Journal: Journal of Clinical Oncology (2014)

e19524 Background: The prevalence of obesity in the world is increasing with each passing year. Body mass index has been proved to be associated with prognosis in various malignancies. Lymphomas are hematopoietic tumors derived from B, T and Natural Killer cells. Lymphoma is the most common of puberty malignancy. The incidence of lymphoma varies with age, geographic region,infectious exposures and racial factors. Our goal is to investigate the effect of body mass index in patients with lymphoma at diagnosis, on overall survival (OS) and progression-free survival (PFS). Methods: Between January 2005 and January 2013, 378 patients with newly diagnosed Hodgkin’s Lymphoma (HL) and Diffuse Non-Hodgkin’s Lymphoma (NHL) at the 19 Mayis University Clinic of Internal Medicine Hematology reviewed retrospectively. Clinical and laboratory information was collected and analyzed. We investigated the effect of disease stage, performance status, the presence of B symptoms, IPI and IPS score, body mass index in patients at diagnosis, on overall survival (OS) and progression-free survival (PFS). Results: Overall, 378 patients were reviewed and analyzed. 120 patients was diagnosed with HL and 258 diagnosed with Diffuse NHL. The median age of Hodgkin’s Lymphoma patients was 42 (18-84), the mean age of Diffuse NHL patients was 60.17 ± 14.92 (18-87), respectively. The average BMI of patients with Hodgkin’s lymphoma was 26.22 ± 5.77 (13.91-42.98) kg /m2, in patients with diffuse NHL it was 26.18 ± 5.45 (14.36-55.78) kg/m2.No statistically significant difference was found between BMI and OS, BMI and PFS in both Hodgkin’s and Diffuse Non-Hodgkin’s Lymphoma patients by the time of diagnosis. Conclusions: We think that there must be more study needs to be done because of the contrasting results of studies dealing with this issue on the relationship between BMI at diagnosis and survival of lymphoma in the literature.
Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study
Authors: Anne Ségolène Cottereau, Laetitia Vercellino, Olivier Casasnovas, Herve Tilly, Pierre Feugier, Christophe Fruchart, Louise Roulin, Lucie Oberic, Gian Matteo Pica, Vincent Ribrag, Julie Abraham, Marc Simon, Hugo Gonzalez, Reda Bouabdallah, Olivier Fitoussi, Catherine Sebban, Armando Lopez-Guillermo, Margaret Macro, Laurence Sahnes, Franck Morschhauser, Judith Trotman, Bernadette Corront, Bachra Choufi, Sylvia Snauwaert, Pascal Godmer, Loïc Chartier, Gilles Salles, Josette Briere, Bertrand Coiffier, Michel Meignan, Catherine Thieblemont
Journal: Blood (2018)
Single-Cell Mass Cytometry Characterizes Phenotypic and Functional Heterogeneity in Acute Myeloid Leukemia at Diagnosis, in Remission and Relapse
Authors: Lina Han, Peng Qiu, Jeffrey L. Jorgensen, Duncan Mak, Jared K Burks, Teresa McQueen, Zhihong Zeng, Farhad Ravandi, Gail J. Roboz, Hagop M. Kantarjian, Steven M. Kornblau, Michael Andreeff, Monica L. Guzman, Marina Y. Konopleva
Journal: Blood (2018)
Adolescent and Young Adult (AYA) Hematopoietic Cell Transplantation (HCT) Recipients Have Similar Quality of Life (QoL) Compared to Older Adults in the First Year Post-Transplantation
Authors: Reema R Mathanda, Betty K. Hamilton, Lisa Rybicki, Anjali S. Advani, Brian J. Bolwell, Amy Colver, Jane Dabney, Christina Ferraro, Aron Flagg, Rabi Hanna, Matt Kalaycio, Christine Lawrence, Linda McLellan, Ronald Sobecks, Navneet S. Majhail
Journal: Blood (2018)
Association of increased progression-free survival in primary glioblastomas with lymphopenia at baseline and activation of NK and NKT cells after dendritic cell immunotherapy.
Authors: Marica Eoli, Serena Pellegatta, Simona Frigerio, Valeria Cuccarini, Lucia Cuppini, Elena Anghileri, Stefania Cuzzubbo, Carlo Antozzi, Maria Grazia Bruzzone, Renato Mantegazza, Eugenio Agostino Parati, Gaetano Finocchiaro
Journal: Journal of Clinical Oncology (2014)

2087 Background: DENDR1 is a phase I-II phase study aimed at evaluating dendritic cell (DC) immunotherapy in patients with first diagnosis of glioblastoma multiforme (GBM). Here we provide results of the interim analysis on 22 patients Methods: Patients with post-surgery volume ≤10 cc underwent leukapheresis before radiotherapy and chemotherapy with temozolomide (TMZ) (Stupp et al, 2005). DC prepared under GMP procedures were loaded with whole tumor lysate (Nava et al, 2012). Three intradermal injections of mature DC were done before adjuvant chemotherapy. The subsequent 4 injections were performed 17 ±3 days after adjuvant TMZ. MRI, clinical and immunological follow-up were performed every 2 months Results: Median age at surgery was 54.5 years (28-69). After a median follow up of 14 months (6-27), the median progression-free survival (PFS) was 9 mo, with PFS6 90% (C. I. 0.78-1.029%) and PFS12 42% (C. I: 0.20-0.64) at Kaplan Meier analysis. Median overall survival (OS) was 22 mo with OS 12 70%. (C. I. 0.50-0.9). RT-TMZ induced significant lymphopenia (<1000 lymphocytes/microl) in 17/22 patients (77.2%). Patients with >1000 lymphocytes/microl (5/22) before first vaccination had shorter PFS than others (p<0.005). Peripheral Blood Lymphocytes (PBLs) were analyzed by flow cytometry to identify CD8+ T cells, NK and NKT cells before and after DC vaccines. The ratio of vaccination/baseline cell frequencies (V/B ratio) was calculated for each patient and the median of all values used as the cut off value to separate patients. Increased V/B ratio for NK cells and NKT cells, but not for CD8 T lymphocytes, was significantly associated with prolonged PFS (median PFS 14 vs 8.0 mo, p=0.01; 15.0 vs 8.0 mo). 2/4 patients with MGMT methylation were in the group of high V/B ratio. Interferon-gamma in peripheral blood was significantly higher in patients with PFS12 (p<0.02). Conclusions: The results show significant positive association between PFS and increased peripheral levels of NK and NKT cells, encouraging the expansion of this study to a larger number of primary GBM. Clinical trial information: 2008-005035-15.
Public perception of cancer care in Poland and Austria: A survey study.
Authors: Jacek Jassem, Mariusz Jedrzejewski, Christine Thallinger, Magda Mrozik, Gabriela Kornek, Christoph Zielinski
Journal: Journal of Clinical Oncology (2014)

e17559 Background: We compared the public perception of cancer care in Poland and Austria. Both countries are members of the European Union (EU), but reflect two extremes in health-related per capita spendings. Moreover, the EUROCARE-5 study (DeAngelis et al., Lancet Oncol, 2013) reported on very discrepant cancer outcomes between the two countries. Methods: A one-time survey was conducted to compare the public perception of cancer treatment in Poland and Austria. In total, 3,649 subjects representing general population, cancer patients and cancer patients´ family members were surveyed. Results: In both countries cancer was considered the most challenging problem of the healthcare system (Poland: 68%, Austria: 63%), and health care was indicated as the most important issue influencing political election decisions (Poland: 35%, Austria: 23%; p<0.001). 26% of Poles and 40% of Austrians reported to have had social contacts with cancer patients within the last 5 years (p<0.001). Polish compared to Austrian cancer patients assessed significantly lower both the overall treatment efficacy (29% and 80%, respectively; p<0.001) and cancer detecting and diagnosing (84% and 44%, respectively; p=0.003). The cancer cure rates estimated by Polish and Austrian citizens were 29% and 44%, respectively (p<0.001). 83% of Polish and 90% of Austrian respondents (p=0.011) demanded more information on cancer treatments. The majority of all interviewed citizens (Poland: 87%, Austria: 85%) thought that cancer patients should have access to all available cancer drugs registered in the EU. However, 18% of Poles vs. 62% of Austrians (p<0.001) agreed with the notion that the available cancer treatment in their countries is of comparable standard to other EU countries. 24% of Poles and 7% of Austrians (p<0.001) identified financial status, age, gender and residence as major factors influencing the availability of cancer treatments. Conclusions: In both countries cancer is considered the most challenging problem of the healthcare system and healthcare issues may strongly influence decisions for political elections. Vast differences in the perception of the two populations on cancer care reflect cancer outcomes and the national per capita spending on health-related issues.
Relation between the size of nonmetastatic lymph nodes and outcomes in patients with stage III colorectal cancer.
Authors: Kazutake Okada, Sotaro Sadahiro, Hiroshi Miyakita, Gota Saito, Akira Tanaka, Toshiyuki Suzuki
Journal: Journal of Clinical Oncology (2018)

822 Background: In stage II colon cancer, retrieval of less than 12 lymph nodes (LNs) is a risk factor for recurrence. We previously reported that the great long-axis diameter of the largest retrieved lymph nodes (maximum LNs) is associated with a higher number of retrieved LNs and better outcomes (Int J Colorectal Dis 2015). We examined whether the long-axis diameter of maximum LNs is a prognostic factor in node-positive stage III colorectal cancer. Methods: The study group comprised 260 patients (pts) with stage III disease who underwent curative resection from 2005 through 2014. Pts who underwent laparoscopic or emergency surgery were excluded. The long-axis diameter was measured on H-E stained specimens and one non-metastatic LN with the greatest long-axis diameter was selected. The cut-off value (COV) for the long-axis diameter was determined by using receiver ROC curves with recurrence or overall mortality as events. Results: Tumors were located in right colon in 86 pts (33%), left colon in 104 pts (40%), and rectum in 70 pts (27%). In pts with rectal cancer, 49 (70%) received chemoradiotherapy (CRT). The mean long-axis diameter was 8.0 ± 3.5 mm. Factors related to the long-axis diameter were tumor location (right colon 9.5 ± 3.8 mm, left colon 7.7 ± 3.4 mm, rectum 6.6 ± 2.4 mm, p &lt; 0.001), CRT (absent 8.4 ± 3.6 mm, present 6.3 ± 2.3 mm, p &lt; 0.001), TNM stage (IIIA 6.6 ± 3.0 mm, IIIB 8.0 ± 3.5 mm, IIIC 8.8 ± 3.7 mm, p = 0.025), and the number of retrieved LNs (less than 12, 6.5 ± 2.9 mm; 12 or more, 9.0 ± 3.5 mm, p &lt; 0.001). The COV for the long-axis diameter from the ROC curves was 8.0 mm. A long-axis diameter of ≥8.0 mm (106 pts 41%) were associated with significantly better outcomes than a long-axis diameter of &lt; 8.0 mm (154 pts 59%) (5y RFS: &lt; 8.0 mm 57%, ≥8.0 mm 70%, p = 0.012). On multivariate analysis, sex (female/male, HR 0.61, p = 0.019), venous invasion (absent/present, HR 0.58, p = 0.042), TNM stage (IIIB/IIIA, HR 3.19, p = 0.021; IIIC/IIIA, HR 3.47, p = 0.033), and the long-axis diameter (≥8.0 mm/ &lt; 8.0 mm, HR 0.55, p = 0.005) were independent prognostic factors. Conclusions: In pts with stage III colorectal cancer, the long-axis diameter of maximum LNs was a prognostic factor. The size of maximum LNs might thus reflect the tumor immunity of the host.
The cost of thromboembolic events in French hospitalized patients with breast or prostate cancer.
Authors: Isabelle Borget, Alexandre Vainchtock, Florian Scotte
Journal: Journal of Clinical Oncology (2014)

6553 Background: Cancer is associated with a high risk of venous thromboembolism. We aimed to determine the number of stays and the cost of hospital management of thromboembolic events (TEEs) occurring in patients with breast cancer (BC) or prostate cancer (PC). Methods: The French national hospital database (PMSI) was analysed in order to identify patients whose BC or PC was diagnosed in 2010 and who were hospitalized for a TEE at least once during the following two years. The numbers of stays induced by a TEE, and the corresponding number of patients hospitalized, were determined using the disease-specific ICD-10 codes. Associated hospital costs were estimated from the perspective of the third-party payer, using the French official tariffs. Results: We identified 62,365 patients with BC and 45,551 patients with PC; in each group, 1,271 (2.0%) and 997 (2.2%), respectively, were hospitalized for a TEE or had a TEE during their hospital stay. During the 2 years of follow-up of these 2,268 patients, 346 (15.3%) were hospitalized for a TEE recurrence. In total, 1,604 stays for BC patients and 1,210 stays for PC patients were analyzed. In BC patients, the mean cost per stay amounted to €3,302 and €2,916 for first event and recurrence, respectively, and in PC patients, €3,611 and €3,363 for first event and recurrence, respectively. In patients who had at least one recurrence, mean hospitalization cost per patient was €5,545 and €5,692 in BC and PC, respectively. Over a 2-year period, the total cost of hospital stays induced by TEEs reached €1.98 million and €1.43 million for BC and PC, respectively. Conclusions: The burden of TEE in cancer patients is high; costs would be reduced by decreasing the occurrence of thromboembolic complications in this at-risk population. Better prevention and follow-up measures may reduce recurrence and TEE costs. Cost of hospital stays for patients with BC or PC and TEE. First event Recurrence Total Breast cancer Mean cost/stay €3,302 €2,916 €3,261 Total cost €1,789,615 €186,620 €1,976,235 Prostate cancer Mean cost/stay €3,611 €3,363 €3,584 Total cost €1,278,397 €147,959 €1,426,357
Colorectal cancer molecular findings in Amazon region: Are we supposed to have so much different data?
Authors: Luis Eduardo Werneck De Carvalho, Aluizio Augusto Pereira Semblano, Matheus Acacio Moreira, Raina Caterina Arrais, Bruno Augusto Pereira Cunha, Rosa Goncalves, Hildebrando Costa Ribeiro Junior
Journal: Journal of Clinical Oncology (2014)

e14634 Background: Colorectal cancer (CRC) is the third most common malignant tumor in the world. The KRAS gene, associated with CRC, located on chromosome 6, having in the codons 12 and 13 the most frequent mutation site, encodes a protein with an important pathogenic role in CRC. The brazilian northern population, especially in the Amazon region has acquired distinctive eating habits when compared to populations of other brazilian regions and other countries, that can lead to important epigenetic alterations. This reasearch aims to present a molecular panel regarding KRAS mutation in patients with colorectal cancer stage III and IV treated at an advanced oncology center in the Amazon region, comparing molecular findings in this population with other panels held in other centers worldwide. Methods: Retrospective, descriptive and quantitative data obtained in medical records of patients in treatment for CRC submitted to immunohistochemistry evaluation, through samples of colorectal tumor from january 2011 to december 2013. Only patients with pathologic confirmation of colorectal cancer stage III and IV were recruited. Results: The present study assessed a sample of 40 patients, of whom only 4 patients (10 %) showed some codon mutation in the KRAS gene. In the southern of Brazil, COURA et al. found 37/37 patients with mutated KRAS gene, the same percentage that SAMMER et al. found in India, where 53/53 patients had KRAS mutation. In the United States, a study of RASHID et al presented mutations in 60/200 (29.9 %) patients. In Japan, HARAD et al. demonstrated 43/120 (35.8%) patients had mutations in KRAS. An italian study of BAZAN et al. showed 74/160 (43.3 %) patients with a mutation in this gene. In China, a study conducted by LIU et al. showed 65/198 (32.8 %) mutated KRAS tumors. Conclusions: Our study found 90% of patients with wild type KRAS gene profile. This KRAS mutation rate data in CRC was not shown until now neither in brazilian samples nor in any other worldwide studies. It should be determined whether some behavioral or epigenetic pattern contributes to gene mutation or if KRAS patients in the study were subjected to a different carcinogenic pathway. Further studies should be conducted considering NRAS and BRAF mutations.
Lung Function Impairment in Pediatric Subjects with Sickle Cell Anemia from Nigeria Is Associatede with Associated Low Steady Haemoglobin
Authors: Baba PD Inusa, Livingstone Gayus Dogara, Ramatu Zubair, Chiara Zuiani, Christoper Audu, Ashel Dache Sunday, Muhammed Zakari Sani, Luigi Castriotta, Michele Arigliani
Journal: Blood (2018)
The European Network for ICU-Related Respiratory Infections (ENIRRIs) ERS Clinical Research Collaboration
Authors: Ignacio Martin-Loeches, Antoni Torres
Journal: European Respiratory Journal (2019)

<b>The European Network for ICU-Related Respiratory Infections (ENIRRIs) ERS Clinical Research Collaboration is addressing the priorities for respiratory infection research in critical care settings</b>http://ow.ly/3KHa30mHryj
Outcome of pts with chronic lymphocytic leukemia (CLL) with abnormal pulmonary radiologic findings.
Authors: Hussam Al-Sharif, Ankit Anand, Karthika raya Linga, Ali Al-Ameri
Journal: Journal of Clinical Oncology (2014)

e18011 Background: Pulmonary radiological findings in CLL are common, previous study showed its around 40%, but since it only occasionally leads to respiratory complaints, the symptoms may be related to other more common diseases. Abnormal findings could be interpreted as pneumonia, which may lead to unnecessary work up. Aim: To study the effect of abnormal pulmonary radiological findings and pulmonary function tests (PFTs) on the survival of patients with CLL. Methods: A retrospective study of CLL pts at Akron General Medical Center, Ohio, USA during 2000-2012. Following IRB approval, pts' charts were reviewed for abnormal pulmonary radiological findings within 2 wks either before or after the diagnosis in addition to abnormal PFT. Overall survival rates were determined by Kaplan-Meier survival analysis. Abnormal radiological findings included were but not limited to infiltrates, atelectasis, lymph nodes, nodules, and fibrosis. PFTs were classified as normal vs. abnormal. Results: 123 pts with CLL were initially included. Pts were followed for 400 weeks, 40 pts (33%) lost to follow up. 83 pts (67%) reviewed, of these, 33pts (40%) were females. 5 pts (6%) were African American, 74 pts (89%) were Caucasian, 4 pts (5%) didn’t have this information on charts. 12 pts (10%) had abnormal radiological findings, 12 pts (100%) caucasian, 4 pts (33%) females. Median survival in pts with radiological findings was 55 wks as compared to 272 wks in pts without. Mean survival was 124 wks for pts with radiological findings as compared to 324 wks in pts without findings. Standard error for pts with findings was 49.2, and 27.81 for pts without. 95% CI for mean was 27.58 -220.58 for pts with findings and 269.89-378.89 for pts without. 95% CI of median for pts with findings was 13.00-142.00 and 196.00-336.00 for pts without findings. P value was 0.0004 for pts with abnormal pulmonary radiological findings. 11pts (9%) found to have abnormal PFT, 10 pts (91%) white,1 pt (9%) did not have this information, 5 (45%) were females. P value was 0.2581 for pts with abnormal PFTs. Conclusions: In our study, CLL pts with abnormal radiological findings had lower survival rates. Abnormal PFTs did not significantly affect survival. More data is needed to confirm these findings.